Aging affects immune response and virus dynamics in COVID-19 patients, study finds

A study examining 1031 hospitalized COVID-19 patients found that aging significantly impacts immune responses, viral dynamics, and the nasal microbiome, with older adults experiencing more severe disease symptoms and delayed viral clearance.

Up and down the ladder: The latest comings and goings

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s

August 11, 2023

FDA accepts Sanofi’s Sarclisa sBLA for priority review

In a Phase III trial, Sanofi’s Sarclisa regimen offered statistically significant PFS improvement in NDMM patients. Credit: Sergiy Palamarchuk/ Shutterstock.com. The US Food and Drug

May 28, 2024

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform – Biotech Investments

Issuer: CureVac / Key word(s): Study results 05.01.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Positive

January 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.